Given the previous selection of bacterial strains due to their probiotic potential in infection in vivo models and mucositis (Acurcio L. B. et al., 2017, Acurcio et al., 2017 LB.; Cordeiro et al., 2018; Valente et al., 2019), and subsequent characterization of the lyophilized fermented product and supplemented with FOS, we decided to investigate its therapeutic potential in a murine model of mucositis induced by 5-FU chemotherapy. Here, FOS is linked to mucositis.